ONC
Beone Medicines Ltd.
An oncology-focused biopharmaceutical company that develops and sells medicines for blood cancers, including Brukinsa, used to treat leukemia and lymphoma. Founded in Beijing in 2010 by John Oyler and Xiaodong Wang, it was originally called BeiGene — a blend of "Beijing" and "gene" — before rebranding as BeOne in 2024, a name chosen to reflect its mission against cancer: "Be" stands for patients' goal to be free of disease, and "One" for uniting people in that fight.
ADRUnderlying: ONCCUSIP: 07725L102HealthcareCN1 holder
American Depositary Receipt (each representing 13 ordinary shares)
Total Value
$210.1K
Total Shares
772
Net Share Change
-838
Activity
1 selling
Investor
Value
Shares
Weight
Change
